Cempra, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference

     Cempra, Inc. to Present at Cowen and Company 33rd Annual Health Care

PR Newswire

CHAPEL HILL, N.C., Feb. 26, 2013

CHAPEL HILL, N.C., Feb. 26, 2013 /PRNewswire/ --Cempra, Inc. (Nasdaq: CEMP)
today announced that Prabhavathi Fernandes, Ph.D., president and chief
executive officer of Cempra, will present at the Cowen and Company 33^rd
Annual Health Care Conference at 2:10 p.m. EST, Monday, March 4, at the Boston
Marriott Copley Place in Boston. Dr. Fernandes will provide an update of the
company's two differentiated antibiotics, solithromycin (CEM-101) for
community-acquired bacterial pneumonia and TAKSTA™ (CEM-102 or fusidic acid)
for the chronic, oral treatment of gram positive pathogens including
methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.

About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company
focused on developing antibiotics to meet critical medical needs in the
treatment of bacterial infectious diseases. Cempra's two lead product
candidates are in advanced clinical development; solithromycin in Phase 3 for
CABP and TAKSTA™ in Phase 2 for prosthetic joint infections. Both seek to
address the need for new treatments targeting drug-resistant bacterial
infections in the hospital and in the community. The company also intends to
use its series of proprietary lead compounds from its novel macrolide library
for uses such as the treatment of chronic inflammatory diseases, endocrine
diseases and gastric motility disorders. Additional information about Cempra
can be found at www.cempra.com.

Investor and Media Contacts:

Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226

Andreas Marathovouniotis
Russo Partners, LLC
(212) 845-4235

SOURCE Cempra, Inc.

Website: http://www.cempra.com
Press spacebar to pause and continue. Press esc to stop.